Symbols

SXTP

60 Degrees·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Consensus Rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SXTP

60 Degrees Pharmaceuticals, Inc.

A growth-oriented specialty pharmaceutical company developing new treatments for infectious diseases

Industry

Pharmaceutical

Established Date

06/01/2022

Listing Date

07/12/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.60degreespharma.com

Security Type

Common stock

Office address

1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036

Business

Introduction

60 Degrees Pharmaceuticals, Inc., was incorporated in Delaware on June 1, 2022 after merging with a limited liability company of the same name. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of infectious diseases. Its product Arakoda (a malaria preventive drug) has been on the market since 2019, and its R&D pipeline also includes other vector, fungal and viral disease projects.

Company Financials

EPS

SXTP has released its 2025 Q1 earnings. EPS was reported at -1.56, versus the expected -0.11, missing expectations. The chart below visualizes how SXTP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SXTP has released its 2025 Q4 earnings report, with revenue of 316.38K, reflecting a YoY change of 16.22%, and net profit of -1.44M, showing a YoY change of 29.77%. The Sankey diagram below clearly presents SXTP's revenue sources and cost distribution.